Acute Biphenotypic Leukemia — Trials

Acute Biphenotypic Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 14%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04874194	Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1	terminated	Phase 1 / Phase 2	24	M.D. Anderson Cancer CenterOTHER	1	Nov 3, 2025	clinicaltrials
NCT04526795	Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia	terminated	Phase 1	19	M.D. Anderson Cancer CenterOTHER	1	Dec 12, 2024	clinicaltrials